🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

AstraZeneca sticks to 2020 outlook, boosted by drug stockpiling

Published 04/29/2020, 02:21 AM
Updated 04/29/2020, 04:50 AM
© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York
AZN
-

By Pushkala Aripaka and Ludwig Burger

(Reuters) - AstraZeneca (L:AZN) topped analysts' estimates for quarterly profit and reiterated its targets for the year on Wednesday, as the British drugmaker benefited from higher demand for some of its medicines during the coronavirus pandemic.

The Cambridge-based drugmaker joined other big pharma firms in either maintaining or raising its forecast for 2020 and said its supply chain had proved resilient to the coronavirus-induced disruptions in the period.

All of its China operations had come quickly back on line, it said, and while it assumed the pandemic would last for several more months, sales have been helped in the short term by stockpiling by distributors.

Revenues would increase by a high single-digit to a low double-digit percentage this year, the company said, comparing favourably to analysts current average forecast of 8.4%, according to Refinitiv data.

Shares rose about 1.5% after the results.

European peers including Bayer (DE:BAYGn) and Novartis (S:NOVN) have also seen an uplift in demand in the quarter, as hospitals moved quickly to stock their shelves.

AstraZeneca's product sales for the first quarter ended March 31 rose 17% to $6.31 billion on a constant-currency basis, as asthma medication Symbicort and cancer drug Tagrisso fared well, helping it beat analysts' overall expectations of $5.89 billion

Newer treatments, including those for diabetes, heart conditions and cancer, have put the company's business on track for its third consecutive year of growth, with a strong line-up in place for future sales.

Revenue from China, a key growth region, rose 17% to $1.42 billion, accounting for about 23% of total revenue.

Like a raft of other drugmakers, AstraZeneca is testing two of its approved treatments as a therapy to help in the outbreak that has so far infected over 3.1 million people and killed more than 210,000.

Drugmakers worldwide are also having to halt or stall existing trials as they divert funds and research into potential COVID-19 treatments, but AstraZeneca said it did not expect any delays to late-stage trials in 2020 and 2021.

Core earnings at the drugmaker rose 21% to $1.05 per share, while total revenue, which also includes payments from tie-ups, rose 17% to $6.35 billion from year earlier.

© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

Analysts on average had expected core earnings of 94 cents per share, according to a company provided consensus of 22 analysts.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.